OncClubAll Oncology NewsPipeline Report
InsightsMedical World NewsOncChatsOncLive News Network®OncLive TVPeer ExchangePodcastsRapid ReadoutsThe Talk
Conference CoverageConference Listing
Giants of Cancer CarePER EventsScientific InterchangesState of the Science Summit / IPCWebinars
Partners
Oncology Live®Oncology FellowsSupplements And Featured PublicationsAll Publications
CME/CE
Biomarker ConsortiumInteractive ToolsLearning ModulesPresentationsSponsored
Print SubscriptioneNewsletter
Biosimilars
Brain Cancer
Breast CancerBreast Cancer
Business Management
CAR T-cell Therapy
COVID-19
Disparities in Cancer Care
Gastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary Cancers
Global Oncology
Gynecologic OncologyGynecologic Oncology
Head & Neck Cancers
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
Immuno-OncologyImmuno-OncologyImmuno-OncologyImmuno-Oncology
Lung Cancer
Melanoma & Skin Cancer
Oncology Nursing News
Pediatric Oncology
Precision Medicine in Oncology®Precision Medicine in Oncology®
Sarcomas/TGCT
Supportive Care
Spotlight -
  • REGISTER TODAY to explore data on a novel second-generation BTK inhibitor for adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
  • Share your views with OncChats
Biosimilars
Brain Cancer
Breast CancerBreast Cancer
Business Management
CAR T-cell Therapy
COVID-19
Disparities in Cancer Care
Gastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary Cancers
Global Oncology
Gynecologic OncologyGynecologic Oncology
Head & Neck Cancers
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
Immuno-OncologyImmuno-OncologyImmuno-OncologyImmuno-Oncology
Lung Cancer
Melanoma & Skin Cancer
Oncology Nursing News
Pediatric Oncology
Precision Medicine in Oncology®Precision Medicine in Oncology®
Sarcomas/TGCT
Supportive Care
    • Partners
    • CME/CE
Advertisement

Emerging Treatment Patterns for Hepatocellular Carcinoma

home / peer-exchange / hcc-emerging-treatment-patterns
Advertisement
Treatment Strategies for Early-Stage HCC

EP. 1: Treatment Strategies for Early-Stage HCC

November 28th 2018
Global Perspective on Locoregional Therapies in HCC

EP. 2: Global Perspective on Locoregional Therapies in HCC

November 28th 2018
Combining TACE With Systemic Therapy in Advanced HCC

EP. 3: Combining TACE With Systemic Therapy in Advanced HCC

November 28th 2018
Locoregional Therapy in HCC: Additional Considerations

EP. 4: Locoregional Therapy in HCC: Additional Considerations

November 28th 2018
Radiotherapy Use in HCC

EP. 5: Radiotherapy Use in HCC

November 28th 2018
Prognostic and Predictive Markers in HCC

EP. 6: Prognostic and Predictive Markers in HCC

November 28th 2018
Advertisement
Sorafenib Initiation After TACE in HCC

EP. 7: Sorafenib Initiation After TACE in HCC

November 28th 2018
Lenvatinib As Up-front Therapy for Unresectable HCC

EP. 8: Lenvatinib As Up-front Therapy for Unresectable HCC

November 28th 2018
Regorafenib Following First-Line Systemic Therapy in HCC

EP. 9: Regorafenib Following First-Line Systemic Therapy in HCC

November 28th 2018
Sequencing With Cabozantinib in Advanced HCC

EP. 10: Sequencing With Cabozantinib in Advanced HCC

November 28th 2018
Ramucirumab After Progression in Advanced HCC

EP. 11: Ramucirumab After Progression in Advanced HCC

November 28th 2018
Considerations for Using Nivolumab in Advanced HCC

EP. 12: Considerations for Using Nivolumab in Advanced HCC

November 28th 2018
Advertisement
Opportunities for Checkpoint Inhibitors in Advanced HCC

EP. 13: Opportunities for Checkpoint Inhibitors in Advanced HCC

November 28th 2018
Emerging Novel Combinations in Advanced HCC

EP. 14: Emerging Novel Combinations in Advanced HCC

November 28th 2018
The Management of HCC: Moving Forward

EP. 15: The Management of HCC: Moving Forward

November 28th 2018

Latest Conference Coverage

KIT Inhibitors Lead to Shift in Treatment of Systemic Mastocytosis

Smoldering Multiple Myeloma Management Hinges on the Debate Between Treatment and Observation

Lung Responses to Atezolizumab/Bevacizumab Linked With OS in HCC and Pulmonary Metastasis

Second-Line Regorafenib Demonstrates Safety in Advanced HCC, Irrespective of Prior Treatment

View More Latest Conference Coverage
Advertise
About OncLive
Editorial Board
CancerNetwork.com
CGTlive.com
CureToday.com
OncNursingNews.com
TargetedOnc.com
Contact Us
Privacy
Terms & Conditions
Do Not Sell My Information
Contact Info

2 Clarke Drive
Cranbury, NJ 08512

609-716-7777

© 2023 MJH Life Sciences

All rights reserved.
Home
About Us
News
Contact